GLP-2 also attenuates chemotherapy-induced mucositis, reduces epithelial permeability, improves intestinal barrier function, and decreases meal-stimulated gastric acid secretion as well as gastrointestinal motility [108], making the hormone a suitable agent for the treatment not only of SBS but also inflammatory bowel diseases and chemotherapy-induced mucositis [28]. This evidence concerns the gene GCG and mucositis.